U.S. Stem Cell (USRM) 10-Q 7 Nov 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 07, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	U.S. STEM CELL, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		341,284,817
Amendment Flag	false
Entity Central Index Key	1,388,319
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	Yes
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 956,615	$ 270,720
Accounts receivable, net	114,991	16,025
Inventory	58,992	42,218
Total current assets	1,130,598	328,963
Property and equipment, net	503,508	20,969
Investments	55,953	67,544
Deposits	10,160	10,160
Total assets	1,700,219	427,636
Current liabilities:
Accounts payable, including $184,054 and $108,504 to related parties, respectively	1,419,711	1,290,292
Accrued expenses	866,089	904,772
Advances, related party	104,901	104,901
Deferred revenue	286,855	126,932
Deferred gain on sale of equipment	128,845	0
Deposits	465,286	465,286
Promissory note, short term portion, net of debt discount of $0 and $71,449, respectively	0	3,551
Notes payable, related party	1,956,726	2,290,285
Notes and capital leases payable, net of debt discount of $72,358 and $103,479, respectively	1,206,518	680,336
Derivative liabilities	0	297,156
Total current liabilities	6,434,931	6,163,511
Long term debt:
Deferred revenue	69,250	71,500
Deferred gain on sale of equipment	182,531	0
Long term deposits	100,000	0
Promissory note, long term portion, net of debt discount of $186,687 and $169,072, respectively	1,211,075	1,228,690
Notes and capital lease payable, long term portion	1,237,895	982,579
Total long term debt	2,800,751	2,282,769
Total liabilities	9,235,682	8,446,280
Commitments and contingencies	0	0
Stockholders’ deficit:
Preferred stock, par value $0.001; 20,000,000 shares authorized, -0- and 20,000,000 issued and outstanding as of September 30, 2017 and December 31, 2016, respectively	0	20,000
Common stock, par value $0.001; 2,000,000,000 shares authorized, 339,301,983 and 127,012,740 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively	339,302	127,013
Additional paid in capital	120,100,363	115,981,103
Accumulated deficit	(127,975,128)	(124,146,760)
Total stockholders’ deficit	(7,535,463)	(8,018,644)
Total liabilities and stockholders’ deficit	$ 1,700,219	$ 427,636

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parentheticals) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Accounts payable, related parties (in Dollars)	$ 184,054	$ 108,504
Debt discount (in Dollars)	$ 72,358	$ 103,479
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	20,000,000
Preferred stock, shares outstanding	0	20,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	339,301,983	127,012,740
Common stock, shares outstanding	339,301,983	127,012,740
Notes Payable, Other Payables [Member]
Debt discount (in Dollars)	$ 0	$ 71,449
Notes Payable, Other Payables [Member]
Debt discount (in Dollars)	$ 186,687	$ 169,072

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue:
Products	$ 527,015	$ 345,274	$ 1,523,004	$ 1,211,609
Services	979,503	384,539	2,524,411	907,372
Total revenue	1,506,518	729,813	4,047,415	2,118,981
Cost of sales	482,932	332,522	1,228,126	722,276
Gross profit	1,023,586	397,291	2,819,289	1,396,705
Cost and operating expenses:
Research and development	3,753	1,847	12,242	9,313
Marketing, general and administrative	2,023,986	1,413,929	3,638,705	2,676,415
Depreciation and amortization	52,882	1,501	124,984	3,926
Total operating expenses	2,080,621	1,417,277	3,775,931	2,689,654
Income (loss) from operations	(1,057,035)	(1,019,986)	(956,642)	(1,292,949)
Other income (expenses):
Gain (loss) on settlement of debt	245,662	(23,133)	(137,198)	49,681
Gain on sale of equipment	32,212	0	75,160	500
Loss on change of fair value of derivative liability	0	(413,217)	(1,891,205)	(269,822)
Income from equity investment	39,400	54,729	178,409	85,927
Loss on litigation settlement	0	0	(316,800)	0
Other income	0	0	0	24,741
Interest expense	(191,933)	(278,798)	(780,092)	(994,713)
Total other income (expenses)	125,341	(660,419)	(2,871,726)	(1,103,686)
Net loss before income taxes	(931,694)	(1,680,405)	(3,828,368)	(2,396,635)
Income taxes (benefit)	0	0	0	0
NET LOSS	$ (931,694)	$ (1,680,405)	$ (3,828,368)	$ (2,396,635)
Net loss per common share, basic and diluted (in Dollars per share)	$ 0	$ (0.09)	$ (0.01)	$ (0.28)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	337,417,859	18,289,275	298,041,880	8,628,866

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - 9 months ended Sep. 30, 2017 - USD ($)	Preferred Stock [Member]	Common Stock [Member]Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]	Common Stock [Member]Common Stock Issued in Settlement of Other Debt [Member]	Common Stock [Member]Common Stock Issued in Settlement of Notes Payable and Accrued Interest [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]	Additional Paid-in Capital [Member]Common Stock Issued in Settlement of Other Debt [Member]	Additional Paid-in Capital [Member]Common Stock Issued in Settlement of Notes Payable and Accrued Interest [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]	Common Stock Issued in Settlement of Other Debt [Member]	Common Stock Issued in Settlement of Notes Payable and Accrued Interest [Member]	Total
Balance at Dec. 31, 2016	$ 20,000				$ 127,013				$ 115,981,103	$ (124,146,760)				$ (8,018,644)
Balance (in Shares) at Dec. 31, 2016	20,000,000				127,012,740
Common stock issued in settlement		$ 12,075	$ 164,271	$ 1,749		$ 680,356	$ 2,081,013	$ 56,852			$ 692,431	$ 2,245,284	$ 58,601
Common stock issued in settlement (in Shares)		12,075,754	164,270,878	1,748,947
Common stock issued upon conversion of preferred stock	$ (20,000)				$ 20,000
Common stock issued upon conversion of preferred stock (in Shares)	(20,000,000)				20,000,000
Common stock issued in settlement of litigation					$ 11,000				305,800					316,800
Common stock issued in settlement of litigation (in Shares)					11,000,000
Proceeds from issuance of common stock					$ 3,194				246,806					250,000
Proceeds from issuance of common stock (in Shares)					3,193,664
Reclassify derivative liability to equity upon payoff of notes payable									185,505					185,505
Stock based compensation									562,928					562,928
Net loss										(3,828,368)				(3,828,368)
Balance at Sep. 30, 2017					$ 339,302				$ 120,100,363	$ (127,975,128)				$ (7,535,463)
Balance (in Shares) at Sep. 30, 2017					339,301,983

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,828,368)	$ (2,396,635)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	124,984	3,926
Bad debt (recoveries) expense	(1,327)	21,204
Discount on convertible debt	167,795	556,910
Change in fair value of derivative liability	1,891,205	269,822
Loss (gain) on settlement of debt	137,198	(49,681)
Gain on sale of equipment	(75,160)	(500)
Related party notes payable issued for services rendered	800,000	800,000
Common stock issued in settlement of litigation	316,800	0
Non cash payment of interest	0	193,946
Net non cash interest added to capital lease	173,511	0
Income on equity investments	(178,409)	(85,927)
Stock based compensation	562,928	329,431
Change in fair value of re-priced employee options	0	934
Changes in operating assets and liabilities:
Receivables	(97,639)	(20,030)
Inventory	(16,774)	(23,008)
Prepaid and other current assets	0	4,832
Accounts payable	519,352	78,504
Accrued expenses	372,360	176,102
Deferred revenue	157,673	26,738
Net cash provided by (used in) operating activities	1,026,129	(113,432)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from (payments to) equity investments	190,000	115,000
Proceeds from sale of property and equipment	400,000	500
Proceeds from long term deposits	100,000	0
Acquisition of property and equipment	(1,162)	(12,581)
Net cash provided by investing activities	688,838	102,919
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes payable	154,785	523,089
Proceeds from sale of common stock	250,000	0
Net proceeds from related party advances	0	15,000
Purchase of treasury stock	0	(7,817)
Repayments of related party notes	(1,083,559)	(103,326)
Repayments of notes payable	(350,298)	(228,814)
Net cash (used in) provided in financing activities	(1,029,072)	198,132
Net increase in cash and cash equivalents	685,895	187,619
Cash and cash equivalents, beginning of period	270,720	58,372
Cash and cash equivalents, end of period	956,615	245,991
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	151,228	49,214
Income taxes paid	0	0
Non cash financing activities:
Sale and leaseback of equipment	619,825	0
Reclassify derivative liability to equity	185,505	0
Common Stock Issued in Settlement of Notes Payable [Member]
Non cash financing activities:
Non-cash financing activities, stock issued	111,972	385,710
Common Stock Issued in Settlement of Accounts Payable [Member]
Non cash financing activities:
Non-cash financing activities, stock issued	692,431	103,516
Common Stock Issued in Settlement of Related Party Notes and Advances Payable [Member]
Non cash financing activities:
Non-cash financing activities, stock issued	58,601	10,000
Common Stock Issued in Settlement of Guarantor Fees [Member]
Non cash financing activities:
Non-cash financing activities, stock issued	$ 316,800	$ 0

NOTE 1 - SIGNIFICANT ACCOUNTING

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	NOTE 1 — SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed financial statements follows: General The accompanying unaudited condensed financial statements of U.S. Stem Cell, Inc. (the “Company”) have been prepared in accordance with the rules and regulations (Regulation S-X) of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results from operations for the three and nine month periods ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year ended December 31, 2017. The unaudited condensed financial statements should be read in conjunction with the December 31, 2016 audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K. Basis and business presentation U.S. Stem Cell, Inc. was incorporated under the laws of the State of Florida in August, 1999. The Company is in the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. The primary business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine/cell therapy training services, revenues realized from an Asset Sale and Lease Agreement related to the segment of the Company business involving collecting, growing and banking cell cultures Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client. The Company’s primary sources of revenue are from the sale of test kits and equipment, training services, patient treatments and laboratory services, and cell banking. Revenues for kits and equipment sold are not recorded until kits and equipment are received by the customer. Revenues from trainings are recognized when the training occurs. Any cash received as a deposit for trainings are recorded by the Company as a liability. Patient treatments and laboratory services revenue are recognized when those services have been completed or satisfied. Revenues for cell banking sales are accounted for as Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. Because the Company sells its services separately, on more than a limited basis and at a price within a narrow range, the Company was able to allocate revenue based on vendor-specific objective evidence of fair value (VSOE). The multiple elements include stem cell banking, dose retrieval and yearly storage fees. At September 30, 2017 and December 31, 2016, the Company had deferred revenues of $356,105 and $198,432, respectively. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Allowance for Doubtful Accounts Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of September 30, 2017 and December 31, 2016, allowance for doubtful accounts was $11,154 and $12,487, respectively. Inventories Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs. Investments The Company follows Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 33 percent member interest ownership of U.S. Stem Cell Clinic, LLC utilizing the equity method of accounting. (See Note 3) Property and Equipment Property and equipment are stated at cost. For leased equipment, assets are the recorded at the estimated present value of the future minimum lease payments. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 15 years. Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of September 30, 2017, there were outstanding stock options to purchase 71,630,770 shares of common stock, 20,305,459 shares of which were vested. (See Note 10). Net Loss per Common Share, basic and diluted The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted income (loss) per share as of September 30, 2017 and 2016 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2017 September 30, 2016 Convertible notes payable - 147,287,847 Series A convertible preferred stock - 20,000,000 Options to purchase common stock 71,630,770 23,555,777 Warrants to purchase common stock 135,996 139,145 Totals 71,766,766 190,982,769 Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. As of September 30, 2017, four customers, one of which is a related party ( US Stem Cell Clinic LLC, a partly owned investment in which the Company holds a 33% member interest), represented For the three months ended September 30, 2017, the Company’s revenues earned from the sale of products and services were $1,506,518, of which one customer represented 10% of the Company’s revenues, which is a related party ( US Stem Cell Clinic LLC, a partly owned investment in which the Company holds a 33% member interest), For the nine months ended September 30, 2017, the Company’s revenues earned from the sale of products and services were $4,047,415, of which two customers represented 10%, and 11% of the Company’s revenues respectively, one of which is a related party ( US Stem Cell Clinic LLC, a partly owned investment in which the Company holds a 33% member interest) Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $3,753 and $12,242 for the three and nine months ended September 30, 2017, respectively; and $1,847 and $9,313 for the three and nine months ended September 30, 2016, respectively. Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2017 and December 31, 2016, the Company did not have any derivative instruments that were designated as hedges. At December 31, 2016 and through March 8, 2017, the Company had outstanding convertible notes and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. At September 30, 2017, there were no outstanding convertible notes or warrants with these features. (See Note 6 and Note 8). Long Term Deposits Long term deposits are comprised of the following: On March 3, 2017, the Company entered into a customer purchase agreement whereby the Company agreed to sell, for $50,000, the first 5,000 customers of the cell banking business after the effective date of the equipment sale/leaseback agreement with rights to purchase additional customers at a price of $20 per customer. There is no reduction in the selling price should the new customers be fewer than 5,000. The effective date of the sale is upon the expiry or early termination of the related equipment lease transaction (See Notes 4 and 6). On March 3, 2017, the Company entered into an asset purchase agreement of intellectual property whereby the Company agreed to sell all of the Company’s worldwide rights, title or interest in certain intellectual and other property (as defined) associated with the cell banking business for $50,000. The effective date of the sale is upon the expiry or early termination of the related equipment lease transaction (See Notes 4 and 6). In connection with the March 3, 2017 asset purchase agreement, the CEO and CSO of US Stem Cell, Inc. were also retained as CEO and CSO of American Stem Cell Centers of Excellence, which is owned by General American Capital Partners (GACP), to help with scientific and successful operational deployment of clinics. The Board of Directors of the Company believes that with continued oversight this will not diminish the responsibilities of the CEO and CSO of the Company and contends that the successful deployment of American Stem Cell Centers of Excellence will lead to the financial value and revenue growth of U.S. Stem Cell, Inc. through sales of its products and services at American Stem Cell Center of Excellence clinics. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. Recent Accounting Pronouncements In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently reviewing the impact of adoption of ASU 2017-11on its financial statements. There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.

NOTE 2 - GOING CONCERN AND MANA

NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements during nine months ended September 30, 2017, the Company incurred net losses of $3,828,368 and has a working capital deficit (current liabilities in excess of current assets) of $5,304,333. These factors among others may indicate that the Company will be unable to continue as a going concern for a reasonable period of time. The Company’s primary source of operating funds in 2016 and 2017 has been from revenue generated from sales and cash proceeds from the sale of common stock and the issuance of convertible and other debt. The Company has experienced net losses and negative cash flows from operations since inception, but expects these conditions to improve in 2018 and beyond as it develops its business model. The Company has stockholders’ deficiencies at September 30, 2017 and requires additional financing to fund future operations. The Company’s existence is dependent upon management’s ability to develop profitable operations, to obtain additional funding sources and realize revenues from the Asset Sale and Lease Agreement described herein Asset Sale and Lease Agreement

NOTE 3 - INVESTMENTS

NOTE 3 - INVESTMENTS	9 Months Ended
	Sep. 30, 2017
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 3 — INVESTMENTS The investment recorded is comprised of a 33% member interest ownership of U.S. Stem Cell Clinic, LLC, accounted for using the equity method of accounting. The investments in 2014 and 2015 of cash and expenses paid on U.S. Stem Cell Clinic, LLC’s behalf were in aggregate of $59,714. The Company’s 33% income earned by U.S. Stem Cell Clinic, LLC member interests was $39,400 and $178,409 for the three and nine months ended September 30, 2017, respectively, $54,729 and $85,927 for the three and nine months ended September 30, 2016, respectively, (inception to date income of $361,239, unaudited) was recorded as other income/expense in the Company’s Statement of Operations in the appropriate periods. In addition, during the nine months ended September 30, 2017, the Company received distributions totaling $190,000 from U.S. Stem Cell Clinic, LLC (inception to date of $365,000, unaudited). The carrying value of the investment at September 30, 2017 and December 31, 2016 was $55,953 and $67,544, respectively. At September 30, 2017 and December 31, 2016, accounts receivable for sales of test kits to U.S. Stem Cell Clinic, LLC was $26,799 and $12,713 respectively; revenues earned from sales to U.S. Stem Clinic, LLC for the three and nine months ended September 30, 2017 were $152,779 and $438,344, respectively; and for the three and nine months ended September 30, 2016 were $142,774 and $303,625, respectively.

NOTE 4 - PROPERTY AND EQUIPMENT

NOTE 4 - PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 — PROPERTY AND EQUIPMENT Property and equipment are recorded on the basis of cost. For financial statement purposes, property, plant and equipment are depreciated using the straight-line method over their estimated useful lives. Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment in accordance with the guidance for impairment of long lived assets. Property and equipment as of September 30, 2017 and December 31, 2016 is summarized as follows: September 30, 2017 December 31, 2016 Laboratory and medical equipment $ 5,590 $ 342,218 Furniture, fixtures and equipment 130,410 130,410 Computer equipment 49,951 48,788 Leased equipment 619,825 - Leasehold improvements 362,046 362,046 1,167,822 883,462 Less accumulated depreciation and amortization (664,314 ) (862,493 ) $ 503,508 $ 20,969 On March 3, 2017, the Company entered into an asset sale and lease agreement (sale/leaseback transaction, the “ Asset Sale and Lease Agreement”) Lab and Medical Equipment Capitalized Lease The Company determined that the transaction was a capitalized lease and accordingly recorded the leased assets and liability based on the estimated present value of the minimum lease payments. In connection with the sale of the lab, medical and other equipment, the Company realized a gain on sale of equipment of $386,535. The gain is recognized ratably over the term of the lease to operations. During the three and nine months ended September 30, 2017, the Company recognized $32,212 and $75,160 respectively, on the gain on sale of equipment. As of September 30, 2017, deferred gain on sale of equipment was $311,376.

NOTE 5 - ACCRUED EXPENSES

NOTE 5 - ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2017
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 5 — ACCRUED EXPENSES Accrued expenses consisted of the following as of September 30, 2017 and December 31, 2016: September 30, 2017 December 31, 2016 Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest $ 223,628 $ 154,296 Interest payable on notes payable 367,300 599,510 Vendor accruals and other 146,420 146,429 Marketing obligation 92,626 - Employee commissions, compensation, etc. 36,115 4,537 $ 866,089 $ 904,772 During the nine months ended September 30, 2017, the Company issued an aggregate of 12,075,754 shares of its common stock in settlement of outstanding accounts payable and accrued expenses. In connection with the issuance, the Company incurred $371,175 net loss in settlement of debt.

NOTE 6 - NOTES AND CAPITAL LEAS

NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTE 6 — NOTES AND CAPITAL LEASE PAYABLE Notes and capital lease payable were comprised of the following as of September 30, 2017 and December 31, 2016: September 30, 2017 December 31, 2016 Seaside Bank note payable. $ 980,000 $ 980,000 Hunton & Williams note(s) payable 604,000 384,972 Daniel James Management notes payable - 7,940 Fourth Man, LLC notes payable - 100,000 Magna Group notes payable - 130,455 Power Up Lending Group notes payable 173,562 159,300 Lab and medical equipment capitalized lease 793,335 - Office equipment finance lease 2,972 3,727 Total notes payable 2,553,869 1,766,394 Less unamortized debt discount (109,456 ) (103,479 ) Total notes payable net of unamortized debt discount 2,444,413 1,662,915 Less current portion (1,206,518 ) (680,336 ) Long term portion $ 1,237,895 $ 982,579 Seaside Bank On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by certain shareholders of the Company. The Company renewed the loan with Seaside National Bank and Trust during the first quarter of 2016 to extend the maturity date to January 11, 2018. Hunton & Williams Notes At December 31, 2016, the Company has two outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822, are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off. On August 31, 2017, the Company and the note holder entered into a Note Forbearance, Modification and Repayment Agreement (“Agreement”). The two notes, $61,150 and $323,822, were payable in one balloon payment upon the date of a written demand and upon certain triggering events occurring. $747,680 $788,276. The note holder agreed to accept full payment of their obligation of over a four (4) year period in 48 monthly installments on an adjusted debt obligation of aggregate $624,000 (reducing the outstanding balance), such payments staggered in amount such that the Company will pay $10,000 monthly the first year, $12,000 monthly the second year, $14,000 monthly the third year, and $16,000 monthly the final year. In addition, the note holder agreed to suspend accrual interest on the notes commencing September 1, 2017. The Agreement remains in full force and effect provided the Company continues to make the monthly payments, there is no event of default as defined in the notes and an agreement to a subordination agreement by NorthStar Biotech Group, LLC, which has been provided. The Company imputed an interest rate of 5% and discounted the note accordingly. The imputed debt discount of $69,701 is amortized to interest expense using the effective interest method. For the three and nine months ended September 30, 2017, the Company amortized $5,172 of debt discounts to current period operations as interest expense. The unamortized debt discount at September 30, 2017 is $64,529. In connection with the Agreement, the Company recognized at aggregate of $233,977 gain on settlement of debt during the three and nine months ended September 30, 2017. Daniel James Management, Fourth Man LLC, and Magna Group During the nine months ended September 30, 2017, the Company paid off $25,000 of the outstanding notes and issued common stock for the conversion of $242,427 of outstanding notes payable and accrued interest (See Note 9). PowerUp Lending Group, Ltd (during this period) On February 22, 2017, the Company entered into a revenue based factoring agreement and received an aggregate of $165,000 (less origination fees of $3,300) in exchange for $221,100 of future receipts relating to monies collected from customers or other third party payors. Under the terms of the factoring agreement, the Company is required to make daily payments equal to $1,316 for 168 business days. The Company received net proceeds of $51,700 along with cancellation of the previous revenue based factoring agreement issued in 2016. In connection with the cancellation of the August 2016 revenue based factoring agreement, the Company incurred a loss in settlement of debt of $41,516. On September 12, 2017, the Company entered into a revenue based factoring agreement and received an aggregate of $137,200 (less origination fees of $2,800) in exchange for $187,600 of future receipts relating to monies collected from customers or other third party payors. Under the terms of the factoring agreement, the Company is required to make daily payments equal to $1,276 for 147 business days. The Company received net proceeds of $103,085 along with cancellation of the previous revenue based factoring agreement issued in February 2017. In connection with the cancellation of the February 2017 revenue based factoring agreement, the Company incurred a gain in settlement of debt of $2,734. The remaining principle balance of the PowerUp Lending Group promissory note payable at September 30, 2017 is $173,562, net of unamortized discount of $44,927. Lab and Medical Equipment Capitalized Lease On March 3, 2017, the Company entered into an asset sale and lease agreement (sale/leaseback transaction; “ Asset Sale and Lease Agreement” The lease includes a base monthly rental payment of $20,000, due the first day of each calendar month. In addition, the Company is required to pay 2.3%, 22.5%, and 31.6% of revenues collected on deposits arising from cell banking business for years 1, 2 and 3, respectively. At the expiration of the lease, the Company is required to return all leased equipment and along with any maintenance records, logs, etc. in the Company’s possession to the lessor with no right of repurchase. The Company determined that the present value of the minimum lease payments exceeded 90% of the estimated fair value of the equipment and therefore classified the equipment sale/lease as a capitalized lease. The effective interest rate of the capitalized lease is estimated at 94.04% based on expected revenue estimations. Minimum lease obligations under the lab and medical lease are as follows: Period ending December 31, 2017 60,000 2018 240,000 2019 240,000 2020 60,000 Total $ 600,000 Promissory Note The Company has a promissory note with an outstanding balance of $1,397,762 and $1,472,762 at September 30, 2017 and December 31, 2016, respectively. The note is unsecured and non-interest bearing with four semi-annual payments of $75,000 beginning on December 31, 2015 with the remaining balance due June 1, 2020. The Company imputed an interest rate of 5% and discounted the promissory note accordingly. The imputed debt discount of $368,615 is amortized to interest expense using the effective interest method. For the three and nine months ended September 30, 2017, the Company amortized $17,616 and $53,834 of debt discounts to current period operations as interest expense, respectively. The unamortized debt discount at September 30, 2017 is $186,687.

NOTE 7 - RELATED PARTY TRANSACT

NOTE 7 - RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 7 — RELATED PARTY TRANSACTIONS Advances As of September 30, 2017 and December 31, 2016, the Company’s officers and directors have provided advances in the aggregate of $104,901 for working capital purposes. The advances are unsecured, due on demand, and non-interest bearing. Notes payable-related party Northstar Biotechnology Group, LLC On February 29, 2012, a promissory note issued to BlueCrest Master Fund Limited was assigned to Northstar Biotechnology Group, LLC (“Northstar”), owned partly by certain directors and existing shareholders of the Company at the time, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267 the (“Note”). On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock. On September 21, 2012, the Company issued 5,000 common stock purchase warrants to Northstar that was treated as additional interest expense upon issuance. On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000 shares of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights. In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing, and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated. Effective October 1, 2012, the effective interest rate was 12.85% per annum. The parties agreed, as of February 28, 2013, to reduce the interest rate to 7% per annum. In connection with the consideration paid, Northstar waived, from the effective date through the earlier of termination or expiration of the agreement, satisfaction of the obligations as described in the forbearance agreement. In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued, which was subsequently increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. In addition, the Company was obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012). In lieu of the initial two payments in preferred stock, the parties agreed to modify the voting rights of the subsequently cancelled Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock. The Company is required to issue additional shares of its common stock (as amended), in lieu of cash, each six month anniversary of the effective date for any accrued and unpaid interest. On March 1, 2017, Northstar and the Company entered into a settlement agreement (“Settlement Agreement “) related to pending litigation (See Note 11). Pursuant to the terms and conditions of the Settlement Agreement, Northstar converted its outstanding Series A Convertible preferred stock, into twenty million (20,000,000) shares of common stock. In addition, and separate and apart from the conversion, Northstar received Eleven Million (11,000,000) shares of the Company’s common stock. NorthStar will receive ten percent (10%) of all Company international sales (based on a gross sales basis). Furthermore, a NorthStar designee, Greg Knutson, was appointed to the Board of Directors of the Company and two Company directors, Michael Tomas and Kristin Comella, will each exercise their prior NorthStar options to each receive a Five percent (5%) Member Interest in NorthStar. The parties agreed to a mutual release and NorthStar agreed to terminate any UCC lien on the Company assets previously filed for the benefit of NorthStar. On March 9, 2017 and April 1, 2017, the Company issued 30,000,000 and 1,000,000 shares of its common stock, respectively, as described above. In connection with the settlement, the Company recorded a loss on litigation settlement of $316,800. On September 30, 2013, the Company issued 8,772 shares of its common stock as payment of $100,000 towards cash advances. On December 24, 2013, the Company issued 3,916 shares of its common stock as payment of accrued interest through June 30, 2013 of $85,447. On April 2, 2014, the Company issued 275 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2014 per the forbearance agreement. On September 17, 2014, the limited waiver and forbearance agreement entered into on October 1, 2012 to provide that the perpetual license on products as described for resale, relicensing and commercialization outside the United States was amended as such on the condition that NorthStar provide certain financing, which financing the Company, in its sole discretion, could decline and retain the license. On October 3, 2014, the Company issued 515 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2014 per the forbearance agreement. On April 3, 2015, the Company issued 1,363 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2015 per the forbearance agreement. On October 2, 2015, the Company issued 4,156 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2015 per the forbearance agreement. On October 7, 2015, the Company issued 34,522 shares of its common stock in settlement of $100,000 principal payment towards the outstanding debt. On April 7, 2016, the Company issued 57,778 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due April 1, 2016 per the forbearance agreement. On October 6, 2016, the Company issued 848,490 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2016 per the forbearance agreement. On April 1, 2017, the Company issued 286,315 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,703 due October 1, 2016 per the forbearance agreement. As of September 30, 2017 and December 31, 2016, the principal of this note was $262,000. Officer and Director Notes September 30, 2017 December 31, 2016 Note payable, Beverly Murphy $ - $ 50,000 Note payable, Mr. Tomas - 81,420 Note payable, Mr. Tomas - 375,000 Note payable, Mr. Tomas 162,078 500,000 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 500,000 - Note payable, Ms. Comella - 221,865 Note payable, Ms. Comella 232,648 300,000 Note payable, Ms. Comella 300,000 - Total $ 1,694,726 $ 2,028,285 Note payable, Ms. Murphy On March 29, 2017, the Company issued 1,748,947 shares of common stock in settlement of $50,000 of outstanding notes payable and accrued interest to Ms. Murphy. Notes payable, Mr. Tomas In 2013, the Company issued a promissory note payable for previous advances and accrued compensation. The promissory note bears interest of 5% per annum and due on demand. During the nine months ended September 30, 2017, the Company paid off remaining outstanding balance of $81,420. On August 1, 2013, the Company issued a $375,000 promissory note due on demand in settlement of accrued compensation. The promissory note bears interest of 5% per annum and is due on demand. During the nine months ended September 30, 2017, the Company paid off the outstanding balance of the promissory note. On July 1, 2014, the Company issued a $500,000 promissory note in settlement of accrued compensation. The promissory note bears interest of 5% per annum and was due on January 1, 2015. During the nine months ended September 30, 2017, the Company paid off $337,922 of the outstanding promissory note. The principal outstanding balance of this note as of September 30, 2017 is $162,078. On September 6, 2016, the Company issued a $500,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due upon demand. The principal outstanding balance of this note as of September 30, 2017 is $500,000. On August 7, 2017, the Company issued a $500,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due one year from date of issuance. The principal outstanding balance of this note as of September 30, 2017 is $500,000. Notes payable, Ms. Comella On July 1, 2014, the Company issued a $300,000 promissory note in settlement of accrued compensation. The promissory note bears interest of 5% per annum and was due on January 1, 2015. During the nine months ended September 30, 2017, the Company paid off the outstanding balance of the promissory note. On September 6, 2016, the Company issued a $300,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and was due upon demand. During the nine months ended September 30, 2017, the Company paid off $67,352 of the outstanding promissory note. The principal outstanding balance of this note as of September 30, 2017 is $232,648. On August 7, 2017, the Company issued a $300,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due one year from date of issuance. The principal outstanding balance of this note as of September 30, 2017 is $300,000.

NOTE 8 - DERIVATIVE LIABILITIES

NOTE 8 - DERIVATIVE LIABILITIES	9 Months Ended
	Sep. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 8 — DERIVATIVE LIABILITIES In fiscal 2016, the Company issued convertible promissory notes. These promissory notes were convertible into common stock, at holders’ option, at a discount to the market price of the Company’s common stock. The Company has identified the embedded derivatives related to these promissory notes relating to certain anti-dilutive (reset) provisions. These embedded derivatives included certain conversion features. The accounting treatment of derivative financial instruments requires that the Company record fair value of the derivatives as of the inception date of these notes and to fair value as of each subsequent reporting date. During the nine months ended September 30, 2017, the remaining promissory notes were converted or paid off in full settlement. The fair value of the embedded derivative at note payoff, in the amount of $185,505, was determined using the Binomial Option Pricing Model based on the following assumptions: (1) dividend yield of 0%; (2) expected volatility of 247.25%, (3) weighted average risk-free interest rate of 0.87%, (4) expected live of 0.54 years, and (5) estimated fair value of the Company’s common stock of $0.0271 per share. The Company reclassified the determined fair value from liability to equity at the time of the payoff. The Company recorded a loss on change in derivative liabilities of $1,891,205 during the nine months ended September 30, 2017. The remaining outstanding derivative liability at September 30, 2017 is $-0- Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company had adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible promissory notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.

NOTE 9 - STOCKHOLDERS' EQUITY

NOTE 9 - STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 9 — STOCKHOLDERS’ EQUITY Preferred stock On March 6, 2017, the Company issued 20,000,000 shares of its common stock upon conversion of the outstanding 20,000,000 shares of Series A Convertible Preferred stock. Common stock During the nine months ended September 30, 2017, the Company issued an aggregate of 164,270,878 shares of its common stock for the conversion of $242,427 of promissory notes payable and related accrued interest. Upon conversion of the promissory notes, the Company recorded an adjustment to the derivative liability in the amount of $2,002,857 (see Note 6). On April 7, 2017, the Company entered into an investment agreement whereby the Company agreed to sell an aggregate of 63,873,275 shares of its common stock for a net purchase price of $5,000,000 ($0.07828 per share). At the execution of the agreement, the Company sold 3,193,664 shares for a purchase price of $250,000 with the remaining sale to be completed within 30 days. The investor has the right to terminate the agreement upon written notice and not complete the purchase. Upon completion of the investment, the investor, or his designee, shall fill one vacancy on the Company’s Board of Directors. On May 18, 2017 the Company received notice from the investor terminating the agreement and, as such, no other shares were sold.

NOTE 10 - STOCK OPTIONS AND WAR

NOTE 10 - STOCK OPTIONS AND WARRANTS	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 10 — STOCK OPTIONS AND WARRANTS Stock Options In December 1999, the Board of Directors and shareholders adopted the 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan, or the Director Plan. The Employee Plan and the Director Plan are collectively referred to herein as the “Plans” The Plans are administered by the Board of Directors and the Compensation Committee. The objectives of the Plans include attracting and retaining key personnel by encouraging stock ownership in the Company by such persons. In February 2010, the Directors & Consultants Plan was amended to extend the termination date of the Plan to December 1, 2011. On April 1, 2013, the Board of Directors approved, subject to subsequently received shareholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan”. The 2013 Omnibus Plan initially reserved up to fifty thousand (50,000) shares of common stock for issuance. On August 4, 2014, the Board of Directors approved to set the reserve to one hundred thousand (100,000) shares of common stock for issuance and to close the 1999 Officers and Employees Stock Option Plan. On February 2, 2015, at the annual meeting of shareholders, the majority of shareholders approved the 2013 Omnibus Equity Compensation Plan. On November 2, 2015, the Board of Directors approved the increase of the reserve under the 2013 Omnibus Plan to five hundred million (500,000,000) shares of common stock for issuance, effective September 16, 2016, approved an addition of twenty five million (25,000,000) shares of common stock to the reserve, effective April 21, 2017, approved an addition of twenty five million (25,000,000) shares of common stock to the reserve and effective August 7, 2017, approved an addition of thirty million (30,000,000) shares of common stock to the reserve. A summary of options at September 30, 2017 and activity during the nine months then ended is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Options outstanding at December 31, 2016 23,555,777 $ 0.03 9.7 Granted 48,075,000 $ 0.025 10.0 Exercised — Forfeited/Expired (7 ) $ 0.15 Options outstanding at September 30, 2017 71,630,770 $ 0.03 9.4 Options exercisable at September 30, 2017 20,305,459 $ 0.04 9.3 Available for grant at September 30, 2017 16,408,070 The following information applies to options outstanding and exercisable at September 30, 2017: Exercise Number Option Outstanding Options Average Remaining Contractual Life (years) Weighted Average Number Options Exercisable Weighted Average Exercise price $ 0.0043 16,200,000 9.36 $ 0.0043 - $ - 0.0196 22,850,000 8.98 0.0196 11,600,000 0.0196 0.03626 31,865,000 9.86 0.03626 8,125,000 0.03626 0.03680 10,000 9.86 0.03680 - 0.03680 0.15402 705,405 8.00 0.15402 580,169 0.15402 19.32 150 7.10 19.32 75 19.32 70.00 100 3.92 70.00 100 70.00 210.00 40 3.87 210.00 40 210.00 680.00 40 2.36 680.00 40 680.00 5,250.00 35 0.55 5,250.00 35 5,250.00 Total 71,630,770 9.37 $ 0.03 20,305,459 $ 0.04 The aggregate intrinsic value of the issued and exercisable options of $318,150 and $20,880, respectively, represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $0.0214 as of September 30, 2017, which would have been received by the option holders had those option holders exercised their options as of that date. On February 6, 2017, the Company granted an aggregate 16,200,000 options to purchase the Company’s common stock at $0.0043 per share to key employees, vesting over 4 years, at grant date anniversary and exercisable over 10 years. The aggregate fair value of $53,271, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 235.22% and Risk free rate: 1.86%. On August 7, 2017, the Company granted an aggregate 23,750,000 options to purchase the Company’s common stock from $0.03626 to $0.0368 per share to key employees, vesting over 4 years, at grant date anniversary and exercisable over 10 years. The aggregate fair value of $860,211, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 259.16% and Risk free rate: 1.81%. On August 7, 2017, the Company granted an aggregate 8,125,000 options to purchase the Company’s common stock at $0.03626 per share to members of the Board of Directors, vesting immediately and exercisable over 10 years. The aggregate fair value of $293,545, determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: 0%; Volatility: 259.16% and Risk free rate: 1.81%. The fair value of all options vesting during the three and nine months ended September 30, 2017 of $396,238 and $562,928 The fair value of all options vesting during the three and nine months ended September 30, 2016 of $188,009 and $329,814, respectively, was charged to current period operations. As of September 30, 2017, the Company had approximately $1,082,572 of total unrecognized compensation cost related to non-vested awards granted under the 2013 Omnibus Plan, which the Company expects to recognize over a weighted average period of 1.92 years. Warrants A summary of common stock purchase warrants at September 30, 2017 and activity during the nine months ended September 30, 2017 is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Outstanding at December 31, 2016 139,145 $ 173.03 5.5 Issued - Exercised - Expired (3,149 ) $ 1,767.71 Outstanding at September 30, 2017 135,996 $ 136.10 4.8 Exercisable at September 30, 2017 134,451 $ 49.30 4.8 The following information applies to common stock purchase warrants outstanding and exercisable at September 30, 2017: Warrants Outstanding Warrants Exercisable Shares Weighted- Average Remaining Contractual Term Weighted- Average Exercise Price Shares Weighted- Average Exercise Price $ 0.01 – $20.00 94,108 5.2 $ 15.54 94,108 $ 15.54 $ 20.01 – $30.00 29,743 4.3 $ 24.52 29,743 $ 24.52 $ 40.01 - $50.00 6,253 2.1 $ 48.36 6,253 $ 48.36 $ 50.01 – $60.00 543 3.8 $ 60.00 543 $ 60.00 $ >$60.00 5,349 3.9 $ 2,988.07 3,804 $ 1,078.38 135,996 4.8 $ 136.10 134,451 $ 49.30 The aggregate intrinsic value of the issued and exercisable warrants of $-0- represents the total pretax intrinsic value, based on warrants with an exercise price less than the Company’s stock price of $0.0214 as of September 30, 2017, which would have been received by the warrant holders had those warrants holders exercised their warrants as of that date.

NOTE 11 - COMMITMENTS AND CONTI

NOTE 11 - COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 11 — COMMITMENTS AND CONTINGENCIES Litigation On August 30, 2016, Northstar Biotech Group, LLC filed suit against the Company seeking a declaratory judgment as to whether its 20,000,000 Series A Preferred Shares were the subject of the Company’s reverse stock split effective November 4, 2015. On March 1, 2017, Northstar and the Company entered into a settlement agreement related to this dispute (the “Settlement Agreement”). Pursuant to the terms and conditions of the Settlement Agreement, Northstar, previously a holder of Company preferred stock, has converted such preferred stock to twenty million (20,000,000) shares of common stock. In addition, and separate and apart from the conversion, Northstar received Eleven Million (11,000,000) shares of common stock. NorthStar will receive ten percent (10%) of all Company international sales (based on a gross sales basis). Furthermore, a NorthStar designee, Greg Knutson, was appointed to the Board of Directors of the Company and two Company directors, Michael Tomas and Kristin Comella, will each exercise their prior NorthStar options to each receive a Five percent (5%) Member Interest in NorthStar. The parties agreed to a mutual release and NorthStar agreed to terminate any UCC lien on the Company assets previously filed for the benefit of NorthStar. The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity. There was no outstanding litigation as of September 30, 2017 other then described above.

NOTE 12 - FAIR VALUE MEASUREMEN

NOTE 12 - FAIR VALUE MEASUREMENT	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 12 — FAIR VALUE MEASUREMENT The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) on January 1, 2008. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements. The carrying value of the Company’s cash and cash equivalents, accounts receivable, accounts payable, short-term borrowings (including convertible notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity. As of September 30, 2017 or December 31, 2016, the Company did not have any items that would be classified as level 1 or 2 disclosures. The Company recognizes its derivative liabilities as level 3 and values its derivatives using the methods discussed in note 8. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Notes 6 and 8 are that of volatility and market price of the underlying common stock of the Company. As of September 30, 2017 and December 31, 2016, the Company did not have any derivative instruments that were designated as hedges. The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of September 30, 2017: Derivative Liability Balance, December 31, 2016 297,156 Total (gains) losses Transfers out of Level 3 upon conversion or payoff of notes payable (2,188,361 ) Mark-to-market at September 30, 2017: 1,891,205 Balance, September 30, 2017 $ - Net loss for the period included in earnings relating to the liabilities held at September 30, 2017 $ (1,891,205 ) Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. The Company’s stock increased approximately 942% from December 31, 2016 to March 8, 2017 (final conversion of convertible notes). As the stock price increases for each of the related derivative instruments, the value to the holder of the instrument generally increases. Stock price is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments. The estimated fair value of these liabilities is sensitive to changes in the Company’s expected volatility. Increases in expected volatility would generally result in a higher fair value measurement.

NOTE 13 - SUBSEQUENT EVENTS

NOTE 13 - SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 13 — SUBSEQUENT EVENTS In October 2017, the Company issued an aggregate of 1,423,647 shares of common stock for services rendered. In October 2017, the Company issued 559,187 shares of common stock as payment of $12,704 Northstar interest.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis and business presentation U.S. Stem Cell, Inc. was incorporated under the laws of the State of Florida in August, 1999. The Company is in the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. The primary business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine/cell therapy training services, revenues realized from an Asset Sale and Lease Agreement related to the segment of the Company business involving collecting, growing and banking cell cultures
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. At the time of each transaction, management assesses whether the fee associated with the transaction is fixed or determinable and whether or not collection is reasonably assured. The assessment of whether the fee is fixed or determinable is based upon the payment terms of the transaction. Collectability is assessed based on a number of factors, including past transaction history with the client and the creditworthiness of the client. The Company’s primary sources of revenue are from the sale of test kits and equipment, training services, patient treatments and laboratory services, and cell banking. Revenues for kits and equipment sold are not recorded until kits and equipment are received by the customer. Revenues from trainings are recognized when the training occurs. Any cash received as a deposit for trainings are recorded by the Company as a liability. Patient treatments and laboratory services revenue are recognized when those services have been completed or satisfied. Revenues for cell banking sales are accounted for as Multiple-Element Arrangements under ASC 605-10 which incorporates Accounting Standards Codification subtopic 605-25, Multiple-Element Arrangements (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. Because the Company sells its services separately, on more than a limited basis and at a price within a narrow range, the Company was able to allocate revenue based on vendor-specific objective evidence of fair value (VSOE). The multiple elements include stem cell banking, dose retrieval and yearly storage fees. At September 30, 2017 and December 31, 2016, the Company had deferred revenues of $356,105 and $198,432, respectively.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Receivables, Policy [Policy Text Block]	Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of September 30, 2017 and December 31, 2016, allowance for doubtful accounts was $11,154 and $12,487, respectively.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.
Equity Method Investments [Policy Text Block]	Investments The Company follows Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 33 percent member interest ownership of U.S. Stem Cell Clinic, LLC utilizing the equity method of accounting. (See Note 3)
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost. For leased equipment, assets are the recorded at the estimated present value of the future minimum lease payments. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 15 years.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of September 30, 2017, there were outstanding stock options to purchase 71,630,770 shares of common stock, 20,305,459 shares of which were vested. (See Note 10).
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Common Share, basic and diluted The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted income (loss) per share as of September 30, 2017 and 2016 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2017 September 30, 2016 Convertible notes payable - 147,287,847 Series A convertible preferred stock - 20,000,000 Options to purchase common stock 71,630,770 23,555,777 Warrants to purchase common stock 135,996 139,145 Totals 71,766,766 190,982,769
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. As of September 30, 2017, four customers, one of which is a related party ( US Stem Cell Clinic LLC, a partly owned investment in which the Company holds a 33% member interest), represented For the three months ended September 30, 2017, the Company’s revenues earned from the sale of products and services were $1,506,518, of which one customer represented 10% of the Company’s revenues, which is a related party ( US Stem Cell Clinic LLC, a partly owned investment in which the Company holds a 33% member interest), For the nine months ended September 30, 2017, the Company’s revenues earned from the sale of products and services were $4,047,415, of which two customers represented 10%, and 11% of the Company’s revenues respectively, one of which is a related party ( US Stem Cell Clinic LLC, a partly owned investment in which the Company holds a 33% member interest)
Research and Development Expense, Policy [Policy Text Block]	Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $3,753 and $12,242 for the three and nine months ended September 30, 2017, respectively; and $1,847 and $9,313 for the three and nine months ended September 30, 2016, respectively.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Derivatives, Policy [Policy Text Block]	Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At September 30, 2017 and December 31, 2016, the Company did not have any derivative instruments that were designated as hedges. At December 31, 2016 and through March 8, 2017, the Company had outstanding convertible notes and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. At September 30, 2017, there were no outstanding convertible notes or warrants with these features. (See Note 6 and Note 8)
Long Term Deposits, Policy [Policy Text Block]	Long Term Deposits Long term deposits are comprised of the following: On March 3, 2017, the Company entered into a customer purchase agreement whereby the Company agreed to sell, for $50,000, the first 5,000 customers of the cell banking business after the effective date of the equipment sale/leaseback agreement with rights to purchase additional customers at a price of $20 per customer. There is no reduction in the selling price should the new customers be fewer than 5,000. The effective date of the sale is upon the expiry or early termination of the related equipment lease transaction (See Notes 4 and 6). On March 3, 2017, the Company entered into an asset purchase agreement of intellectual property whereby the Company agreed to sell all of the Company’s worldwide rights, title or interest in certain intellectual and other property (as defined) associated with the cell banking business for $50,000. The effective date of the sale is upon the expiry or early termination of the related equipment lease transaction (See Notes 4 and 6). In connection with the March 3, 2017 asset purchase agreement, the CEO and CSO of US Stem Cell, Inc. were also retained as CEO and CSO of American Stem Cell Centers of Excellence, which is owned by General American Capital Partners (GACP), to help with scientific and successful operational deployment of clinics. The Board of Directors of the Company believes that with continued oversight this will not diminish the responsibilities of the CEO and CSO of the Company and contends that the successful deployment of American Stem Cell Centers of Excellence will lead to the financial value and revenue growth of U.S. Stem Cell, Inc. through sales of its products and services at American Stem Cell Center of Excellence clinics.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently reviewing the impact of adoption of ASU 2017-11on its financial statements. There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed.

NOTE 1 - SIGNIFICANT ACCOUNTI21

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: September 30, 2017 September 30, 2016 Convertible notes payable - 147,287,847 Series A convertible preferred stock - 20,000,000 Options to purchase common stock 71,630,770 23,555,777 Warrants to purchase common stock 135,996 139,145 Totals 71,766,766 190,982,769

NOTE 4 - PROPERTY AND EQUIPME22

NOTE 4 - PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of September 30, 2017 and December 31, 2016 is summarized as follows: September 30, 2017 December 31, 2016 Laboratory and medical equipment $ 5,590 $ 342,218 Furniture, fixtures and equipment 130,410 130,410 Computer equipment 49,951 48,788 Leased equipment 619,825 - Leasehold improvements 362,046 362,046 1,167,822 883,462 Less accumulated depreciation and amortization (664,314 ) (862,493 ) $ 503,508 $ 20,969

NOTE 5 - ACCRUED EXPENSES (Tabl

NOTE 5 - ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2017
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consisted of the following as of September 30, 2017 and December 31, 2016: September 30, 2017 December 31, 2016 Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest $ 223,628 $ 154,296 Interest payable on notes payable 367,300 599,510 Vendor accruals and other 146,420 146,429 Marketing obligation 92,626 - Employee commissions, compensation, etc. 36,115 4,537 $ 866,089 $ 904,772

NOTE 6 - NOTES AND CAPITAL LE24

NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Notes and capital lease payable were comprised of the following as of September 30, 2017 and December 31, 2016: September 30, 2017 December 31, 2016 Seaside Bank note payable. $ 980,000 $ 980,000 Hunton & Williams note(s) payable 604,000 384,972 Daniel James Management notes payable - 7,940 Fourth Man, LLC notes payable - 100,000 Magna Group notes payable - 130,455 Power Up Lending Group notes payable 173,562 159,300 Lab and medical equipment capitalized lease 793,335 - Office equipment finance lease 2,972 3,727 Total notes payable 2,553,869 1,766,394 Less unamortized debt discount (109,456 ) (103,479 ) Total notes payable net of unamortized debt discount 2,444,413 1,662,915 Less current portion (1,206,518 ) (680,336 ) Long term portion $ 1,237,895 $ 982,579
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	Minimum lease obligations under the lab and medical lease are as follows: Period ending December 31, 2017 60,000 2018 240,000 2019 240,000 2020 60,000 Total $ 600,000

NOTE 7 - RELATED PARTY TRANSA25

NOTE 7 - RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	Officer and Director Notes September 30, 2017 December 31, 2016 Note payable, Beverly Murphy $ - $ 50,000 Note payable, Mr. Tomas - 81,420 Note payable, Mr. Tomas - 375,000 Note payable, Mr. Tomas 162,078 500,000 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 500,000 - Note payable, Ms. Comella - 221,865 Note payable, Ms. Comella 232,648 300,000 Note payable, Ms. Comella 300,000 - Total $ 1,694,726 $ 2,028,285

NOTE 10 - STOCK OPTIONS AND W26

NOTE 10 - STOCK OPTIONS AND WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of options at September 30, 2017 and activity during the nine months then ended is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Options outstanding at December 31, 2016 23,555,777 $ 0.03 9.7 Granted 48,075,000 $ 0.025 10.0 Exercised — Forfeited/Expired (7 ) $ 0.15 Options outstanding at September 30, 2017 71,630,770 $ 0.03 9.4 Options exercisable at September 30, 2017 20,305,459 $ 0.04 9.3 Available for grant at September 30, 2017 16,408,070
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following information applies to options outstanding and exercisable at September 30, 2017: Exercise Number Option Outstanding Options Average Remaining Contractual Life (years) Weighted Average Number Options Exercisable Weighted Average Exercise price $ 0.0043 16,200,000 9.36 $ 0.0043 - $ - 0.0196 22,850,000 8.98 0.0196 11,600,000 0.0196 0.03626 31,865,000 9.86 0.03626 8,125,000 0.03626 0.03680 10,000 9.86 0.03680 - 0.03680 0.15402 705,405 8.00 0.15402 580,169 0.15402 19.32 150 7.10 19.32 75 19.32 70.00 100 3.92 70.00 100 70.00 210.00 40 3.87 210.00 40 210.00 680.00 40 2.36 680.00 40 680.00 5,250.00 35 0.55 5,250.00 35 5,250.00 Total 71,630,770 9.37 $ 0.03 20,305,459 $ 0.04
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of common stock purchase warrants at September 30, 2017 and activity during the nine months ended September 30, 2017 is presented below: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Outstanding at December 31, 2016 139,145 $ 173.03 5.5 Issued - Exercised - Expired (3,149 ) $ 1,767.71 Outstanding at September 30, 2017 135,996 $ 136.10 4.8 Exercisable at September 30, 2017 134,451 $ 49.30 4.8
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	The following information applies to common stock purchase warrants outstanding and exercisable at September 30, 2017: Warrants Outstanding Warrants Exercisable Shares Weighted- Average Remaining Contractual Term Weighted- Average Exercise Price Shares Weighted- Average Exercise Price $ 0.01 – $20.00 94,108 5.2 $ 15.54 94,108 $ 15.54 $ 20.01 – $30.00 29,743 4.3 $ 24.52 29,743 $ 24.52 $ 40.01 - $50.00 6,253 2.1 $ 48.36 6,253 $ 48.36 $ 50.01 – $60.00 543 3.8 $ 60.00 543 $ 60.00 $ >$60.00 5,349 3.9 $ 2,988.07 3,804 $ 1,078.38 135,996 4.8 $ 136.10 134,451 $ 49.30

NOTE 12 - FAIR VALUE MEASUREM27

NOTE 12 - FAIR VALUE MEASUREMENT (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of September 30, 2017: Derivative Liability Balance, December 31, 2016 297,156 Total (gains) losses Transfers out of Level 3 upon conversion or payoff of notes payable (2,188,361 ) Mark-to-market at September 30, 2017: 1,891,205 Balance, September 30, 2017 $ - Net loss for the period included in earnings relating to the liabilities held at September 30, 2017 $ (1,891,205 )

NOTE 1 - SIGNIFICANT ACCOUNTI28

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Mar. 03, 2017	Dec. 31, 2015
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Deferred Revenue (in Dollars)	$ 356,105		$ 356,105		$ 198,432
Allowance for Doubtful Accounts Receivable, Current (in Dollars)	$ 11,154		$ 11,154		$ 12,487
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)	71,630,770		71,630,770				23,555,777
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in Shares)	20,305,459		20,305,459
Research and Development Expense (in Dollars)	$ 3,753	$ 1,847	$ 12,242	$ 9,313
Sale Leaseback Transaction, Net Book Value (in Dollars)	$ 50,000		$ 50,000			$ 400,000
Minimum [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life			3 years
Maximum [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life			15 years
Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage			77.00%		83.00%
Sales Revenue, Goods, Net [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage	33.00%	18.00%		13.00%
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Revenues (in Dollars)	$ 1,506,518	$ 729,813	$ 4,047,415	$ 2,118,981
U.S. Stem Cell Clinic, LLC [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	33.00%		33.00%
Revenues (in Dollars)	$ 152,779	$ 142,774	$ 438,344	$ 303,625
Customer One [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage			25.00%		45.00%
Customer One [Member] | Sales Revenue, Goods, Net [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage			10.00%
Customer Two [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage			15.00%		13.00%
Customer Two [Member] | Sales Revenue, Goods, Net [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage	10.00%		11.00%
Customer Three [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage			16.00%		13.00%
Customer Four [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Concentration Risk, Percentage			21.00%		12.00%
U.S. Stem Cell Clinic, LLC [Member]
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	33.00%		33.00%

NOTE 1 - SIGNIFICANT ACCOUNTI29

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	71,766,766	190,982,769
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	147,287,847
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	20,000,000
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	71,630,770	23,555,777
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	135,996	139,145

NOTE 2 - GOING CONCERN AND MA30

NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Income (Loss) Attributable to Parent	$ (931,694)	$ (1,680,405)	$ (3,828,368)	$ (2,396,635)
Working Capital (Deficit)	$ (5,304,333)		$ (5,304,333)

NOTE 3 - INVESTMENTS (Details)

NOTE 3 - INVESTMENTS (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended	217 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2017	Dec. 31, 2016
NOTE 3 - INVESTMENTS (Details) [Line Items]
Payments for (Proceeds from) Investments			$ (190,000)	$ (115,000)
Income (Loss) from Equity Method Investments	$ 39,400	$ 54,729	178,409	85,927
Investments	$ 55,953		$ 55,953			$ 55,953	$ 67,544
U.S. Stem Cell Clinic, LLC [Member]
NOTE 3 - INVESTMENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage	33.00%		33.00%			33.00%
Payments for (Proceeds from) Investments					$ 59,714
Income (Loss) from Equity Method Investments						$ 361,239
Proceeds from Equity Method Investment, Distribution			$ 190,000			365,000
Accounts Receivable, Net	$ 26,799		26,799			$ 26,799	$ 12,713
Revenues	$ 152,779	$ 142,774	$ 438,344	$ 303,625

NOTE 4 - PROPERTY AND EQUIPME32

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - USD ($)	Mar. 03, 2017	Sep. 30, 2017	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Sale Leaseback Transaction, Net Book Value	$ 400,000	$ 50,000	$ 50,000
Sale Leaseback Transaction, Lease Terms	leased back the sold equipment over a three year term
Sale Leaseback Transaction, Deferred Gain, Gross	$ 386,535
Sale Leaseback Transaction, Current Period Gain Recognized		32,212	75,160
Sale Leaseback Transaction, Deferred Gain, Net		$ 311,376	$ 311,376

NOTE 4 - PROPERTY AND EQUIPME33

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property and Equipment - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Schedule of Property and Equipment [Abstract]
Laboratory and medical equipment	$ 5,590	$ 342,218
Furniture, fixtures and equipment	130,410	130,410
Computer equipment	49,951	48,788
Leased equipment	619,825	0
Leasehold improvements	362,046	362,046
	1,167,822	883,462
Less accumulated depreciation and amortization	(664,314)	(862,493)
	$ 503,508	$ 20,969

NOTE 5 - ACCRUED EXPENSES (Deta

NOTE 5 - ACCRUED EXPENSES (Details) - USD ($)	Oct. 07, 2015	Apr. 30, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	34,522	286,315
Gain (Loss) on Extinguishment of Debt			$ 245,662	$ (23,133)	$ (137,198)	$ 49,681
Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]
NOTE 5 - ACCRUED EXPENSES (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued					12,075,754
Gain (Loss) on Extinguishment of Debt					$ (371,175)

NOTE 5 - ACCRUED EXPENSES (De35

NOTE 5 - ACCRUED EXPENSES (Details) - Schedule of Accrued Liabilities - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Schedule of Accrued Liabilities [Abstract]
Amounts payable to the Guarantors of the Company’s loan agreement with Bank of America and Seaside Bank, including fees and interest	$ 223,628	$ 154,296
Interest payable on notes payable	367,300	599,510
Vendor accruals and other	146,420	146,429
Marketing obligation	92,626	0
Employee commissions, compensation, etc.	36,115	4,537
	$ 866,089	$ 904,772

NOTE 6 - NOTES AND CAPITAL LE36

NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details)	Sep. 12, 2017USD ($)	Mar. 03, 2017USD ($)	Feb. 22, 2017USD ($)	Oct. 07, 2015USD ($)	Apr. 30, 2017USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Mar. 31, 2016	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)	Aug. 31, 2017USD ($)	Dec. 31, 2015USD ($)	Oct. 25, 2010USD ($)
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Notes Payable						$ 2,553,869			$ 2,553,869		$ 1,766,394
Debt Instrument, Unamortized Discount						109,456			109,456		103,479
Amortization of Debt Discount (Premium)									167,795	$ 556,910
Debt Conversion, Original Debt, Amount				$ 100,000	$ 12,703
Gain (Loss) on Extinguishment of Debt						245,662	$ (23,133)		(137,198)	$ 49,681
Repayments of Long-term Capital Lease Obligations									151,169
Capital Lease Obligations Incurred									324,680
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments						793,335			793,335
Power Up Lending Group Notes Payable [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Notes Payable						173,562			173,562
Debt Instrument, Unamortized Discount						44,927			44,927
Revenue Based Factoring Agreement [Member] | Power Up Lending Group Notes Payable [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount	$ 187,600		$ 221,100
Debt Instrument, Payment Terms	Under the terms of the factoring agreement, the Company is required to make daily payments equal to $1,276 for 147 business days.		Under the terms of the factoring agreement, the Company is required to make daily payments equal to $1,316 for 168 business days
Proceeds from Issuance of Debt	$ 137,200		$ 165,000
Debt Instrument, Fee Amount	2,800		$ 3,300
Proceeds from Debt, Net of Issuance Costs	103,085
Gain (Loss) on Extinguishment of Debt	$ 2,734
Notes Payable to Banks [Member] | Seaside National Bank and Trust [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount														$ 980,000
Debt Instrument, Interest Rate, Stated Percentage														4.25%
Debt Instrument, Maturity Date								Jan. 11, 2018
Notes Payable						980,000			$ 980,000		980,000
Notes Payable, Other Payables [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Debt Instrument, Maturity Date									Jun. 1, 2020
Notes Payable						1,397,762			$ 1,397,762		$ 1,472,762
Debt Instrument, Unamortized Discount						186,687			186,687				$ 368,615
Amortization of Debt Discount (Premium)						$ 17,616			$ 53,834
Debt Instrument, Frequency of Periodic Payment									four semi-annual
Debt Instrument, Periodic Payment									$ 75,000
Debt Instrument, Date of First Required Payment									Dec. 31, 2015
Debt Instrument, Imputed Interest, Stated Percentage						5.00%			5.00%
Notes Payable, Other Payables [Member] | Hunton & Williams Notes [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage						8.00%			8.00%		8.00%
Number of Outstanding Notes Payable						2			2		2
Notes Payable						$ 604,000			$ 604,000		$ 384,972
Debt Instrument, Payment Terms									payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.		payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar (or successor) Loan is paid off.
Other Notes Payable												$ 747,680
Accounts Payable to Debt Holders												40,596
Total Notes, Interest and Accounts Payable												$ 788,276
Debt Instrument, Description									The note holder agreed to accept full payment of their obligation of over a four (4) year period in 48 monthly installments on an adjusted debt obligation of aggregate $624,000 (reducing the outstanding balance), such payments staggered in amount such that the Company will pay $10,000 monthly the first year, $12,000 monthly the second year, $14,000 monthly the third year, and $16,000 monthly the final year. In addition, the note holder agreed to suspend accrual interest on the notes commencing September 1, 2017.
Imputed Interest, Rate									5.00%
Debt Instrument, Unamortized Discount						69,701			$ 69,701
Amortization of Debt Discount (Premium)						5,172			64,529
Gains (Losses) on Restructuring of Debt						233,977			233,977
Notes Payable, Other Payables [Member] | Hunton & Williams Note #1 [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Notes Payable						61,150			61,150		$ 61,150
Notes Payable, Other Payables [Member] | Hunton & Williams Note #2 [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Notes Payable						323,822			323,822		323,822
Notes Payable, Other Payables [Member] | Power Up Lending Group Notes Payable [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Notes Payable						173,562			173,562		159,300
Convertible Debt [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Repayments of Convertible Debt									25,000
Debt Conversion, Original Debt, Amount									242,427
Convertible Debt [Member] | Revenue Based Factoring Agreement [Member] | Power Up Lending Group Notes Payable [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Proceeds from Debt, Net of Issuance Costs									51,700
Gain (Loss) on Extinguishment of Debt									(41,516)
Capital Lease Obligations [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount		$ 400,000
Notes Payable						$ 793,335			$ 793,335		$ 0
Debt Instrument, Term		3 years
Capital Lease Obligations		$ 619,825
Debt Instrument, Interest Rate, Effective Percentage		94.04%				75.73%			75.73%
Other Noncash Expense									$ 173,511
Sale Leaseback Transaction, Monthly Rental Payments		$ 20,000
Capital Lease Obligations [Member] | Revenue Precentage, Year One [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Sale Leaseback Transaction, Rate of Revenues to be Paid		2.30%
Capital Lease Obligations [Member] | Revenue Precentage, Year Two [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Sale Leaseback Transaction, Rate of Revenues to be Paid		22.50%
Capital Lease Obligations [Member] | Revenue Precentage, Year Three [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) [Line Items]
Sale Leaseback Transaction, Rate of Revenues to be Paid		31.60%

NOTE 6 - NOTES AND CAPITAL LE37

NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	$ 2,553,869	$ 1,766,394
Less unamortized debt discount	(109,456)	(103,479)
Total notes payable net of unamortized debt discount	2,444,413	1,662,915
Less current portion	(1,206,518)	(680,336)
Long term portion	1,237,895	982,579
Power Up Lending Group Notes Payable [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	173,562
Less unamortized debt discount	(44,927)
Equipment Finance Lease [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	2,972	3,727
Notes Payable to Banks [Member] | Seaside National Bank and Trust [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	980,000	980,000
Notes Payable, Other Payables [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	1,397,762	1,472,762
Less unamortized debt discount	(186,687)		$ (368,615)
Notes Payable, Other Payables [Member] | Hunton & Williams Notes [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	604,000	384,972
Less unamortized debt discount	(69,701)
Notes Payable, Other Payables [Member] | Power Up Lending Group Notes Payable [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	173,562	159,300
Convertible Debt [Member] | Daniel James Management Notes Payable [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	0	7,940
Convertible Debt [Member] | Fourth Man, LLC Notes Payable [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	0	100,000
Convertible Debt [Member] | Magna Group Notes Payable [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	0	130,455
Capital Lease Obligations [Member]
NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Notes Payable [Line Items]
Notes Payable, Gross	$ 793,335	$ 0

NOTE 6 - NOTES AND CAPITAL LE38

NOTE 6 - NOTES AND CAPITAL LEASE PAYABLE (Details) - Schedule of Future Minimum Lease Payments for Capital Leases	Sep. 30, 2017USD ($)
Schedule of Future Minimum Lease Payments for Capital Leases [Abstract]
2,017	$ 60,000
2,018	240,000
2,019	240,000
2,020	60,000
Total	$ 600,000

NOTE 7 - RELATED PARTY TRANSA39

NOTE 7 - RELATED PARTY TRANSACTIONS (Details) - USD ($)	Aug. 07, 2017	Apr. 01, 2017	Mar. 29, 2017	Mar. 09, 2017	Mar. 01, 2017	Oct. 06, 2016	Apr. 07, 2016	Oct. 07, 2015	Oct. 02, 2015	Apr. 03, 2015	Oct. 03, 2014	Jul. 01, 2014	Apr. 02, 2014	Dec. 24, 2013	Sep. 30, 2013	Oct. 01, 2012	Sep. 21, 2012	Mar. 30, 2012	Apr. 30, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Sep. 06, 2016	Dec. 31, 2015	Dec. 31, 2013	Aug. 01, 2013	Feb. 28, 2013	Feb. 29, 2012
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Due to Related Parties, Current																				$ 104,901		$ 104,901		$ 104,901
Class of Warrant or Rights, Granted (in Shares)																						0
Preferred Stock, Shares Authorized (in Shares)																				20,000,000		20,000,000		20,000,000		20,000,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares)								34,522											286,315
Gain (Loss) Related to Litigation Settlement																				$ 0	$ 0	$ (316,800)	$ 0
Debt Conversion, Original Debt, Amount								$ 100,000											$ 12,703
Notes Payable, Related Parties																				1,694,726		1,694,726		$ 2,028,285
Repayments of Related Party Debt																						$ 1,083,559	$ 103,326
Series A Preferred Stock [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Preferred Stock, Voting Rights																modify the voting rights of the subsequently cancelled Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stock holders to 25 votes per share on matters to be voted on by the common stock holders and all prior and subsequent payments of interest will be in common stock
Northstar [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Percentage of Revenues to be Received as Royalty					10.00%
Debt Conversion, Converted Instrument, Shares Issued (in Shares)					20,000,000
Stock Issued During Period, Shares, Other (in Shares)		1,000,000		30,000,000	11,000,000
Number of Directors					2
Equity Method Investment, Ownership Percentage					5.00%
Ms. Murphy [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)			1,748,947
Debt Conversion, Original Debt, Amount			$ 50,000
Chief Scientific Officer [Member] | Note Payable #1 [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount												$ 300,000
Notes Payable, Other Payables [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Maturity Date																						Jun. 1, 2020
Notes Payable, Other Payables [Member] | Affiliated Entity [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																														$ 544,267
Debt Instrument, Payment Terms																Company was obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six month anniversary of the effective date (October 1, 2012).		agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock.
Class of Warrant or Rights, Granted (in Shares)																	5,000
Debt Instrument, Debt Default, Description of Violation or Event of Default																entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000 shares of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights.In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing, and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.
Percentage of Revenues to be Received as Royalty																8.00%
Debt Instrument, Interest Rate, Stated Percentage																12.85%													7.00%
Debt Conversion, Converted Instrument, Shares Issued (in Shares)														3,916	8,772
Debt Conversion, Original Debt, Amount														$ 85,447	$ 100,000
Notes Payable, Related Parties																				262,000		$ 262,000		262,000
Notes Payable, Other Payables [Member] | Ms. Murphy [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Notes Payable, Related Parties																				0		0		50,000
Notes Payable, Other Payables [Member] | Chief Executive Officer [Member] | Note Payable #1 [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																											5.00%
Notes Payable, Related Parties																				0		0		81,420
Repayments of Related Party Debt																						81,420
Notes Payable, Other Payables [Member] | Chief Executive Officer [Member] | Note Payable #2 [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																												$ 375,000
Debt Instrument, Interest Rate, Stated Percentage																												5.00%
Notes Payable, Related Parties																				0		0		375,000
Notes Payable, Other Payables [Member] | Chief Executive Officer [Member] | Note Payable #3 [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount												$ 500,000
Debt Instrument, Interest Rate, Stated Percentage												5.00%
Notes Payable, Related Parties																				162,078		162,078		500,000
Repayments of Related Party Debt																						337,922
Debt Instrument, Maturity Date												Jan. 1, 2015
Notes Payable, Other Payables [Member] | Chief Executive Officer [Member] | Note Payable #4 [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																									$ 500,000
Debt Instrument, Interest Rate, Stated Percentage																									5.00%
Notes Payable, Related Parties																				500,000		500,000		500,000
Notes Payable, Other Payables [Member] | Chief Executive Officer [Member] | Note Payable #5 [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount	$ 500,000
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Notes Payable, Related Parties																				500,000		500,000		0
Debt Instrument, Term	1 year
Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member] | Note Payable #1 [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage												5.00%
Notes Payable, Related Parties																				0		0		221,865
Debt Instrument, Maturity Date												Jan. 1, 2015
Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member] | Note Payable #2 [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																									$ 300,000
Debt Instrument, Interest Rate, Stated Percentage																									5.00%
Notes Payable, Related Parties																				232,648		232,648		300,000
Repayments of Related Party Debt																						67,352
Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member] | Note Payable #3 [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount	$ 300,000
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Notes Payable, Related Parties																				$ 300,000		$ 300,000		$ 0
Debt Instrument, Term	1 year
Notes Payable, Other Payables [Member] | Interest [Member] | Affiliated Entity [Member]
NOTE 7 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)						848,490	57,778		4,156	1,363	515		275
Debt Conversion, Original Debt, Amount						$ 12,705			$ 12,705	$ 12,635	$ 12,705		$ 12,635
Debt Conversion, Converted Instrument, Amount							$ 12,705

NOTE 7 - RELATED PARTY TRANSA40

NOTE 7 - RELATED PARTY TRANSACTIONS (Details) - Schedule of Related Party Notes Payable - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Related Party Transaction [Line Items]
Notes Payable, Related Party	$ 1,694,726	$ 2,028,285
Notes Payable, Other Payables [Member] | Ms. Murphy [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	0	50,000
Notes Payable, Other Payables [Member] | Chief Executive Officer [Member] | Note Payable #1 [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	0	81,420
Notes Payable, Other Payables [Member] | Chief Executive Officer [Member] | Note Payable #2 [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	0	375,000
Notes Payable, Other Payables [Member] | Chief Executive Officer [Member] | Note Payable #3 [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	162,078	500,000
Notes Payable, Other Payables [Member] | Chief Executive Officer [Member] | Note Payable #4 [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	500,000	500,000
Notes Payable, Other Payables [Member] | Chief Executive Officer [Member] | Note Payable #5 [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	500,000	0
Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member] | Note Payable #1 [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	0	221,865
Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member] | Note Payable #2 [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	232,648	300,000
Notes Payable, Other Payables [Member] | Chief Scientific Officer [Member] | Note Payable #3 [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	$ 300,000	$ 0

NOTE 8 - DERIVATIVE LIABILITI41

NOTE 8 - DERIVATIVE LIABILITIES (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
NOTE 8 - DERIVATIVE LIABILITIES (Details) [Line Items]
Share Price	$ 0.0214
Derivative Liability, Current	$ 0	$ 297,156
Notes Payable, Other Payables [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 8 - DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative, Net	$ 185,505
Fair Value Assumptions, Expected Dividend Rate	0.00%
Fair Value Assumptions, Expected Volatility Rate	247.25%
Derivative, Gain (Loss) on Derivative, Net	$ 1,891,205
Notes Payable, Other Payables [Member] | Embedded Derivative Financial Instruments [Member] | Minimum [Member]
NOTE 8 - DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate	0.87%
Share Price	$ 0.0271
Notes Payable, Other Payables [Member] | Embedded Derivative Financial Instruments [Member] | Maximum [Member]
NOTE 8 - DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Expected Term	197 days

NOTE 9 - STOCKHOLDERS' EQUITY (

NOTE 9 - STOCKHOLDERS' EQUITY (Details) - USD ($)	Apr. 07, 2017	Mar. 06, 2017	Oct. 07, 2015	Apr. 30, 2017	Sep. 30, 2017
NOTE 9 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Conversion of Stock, Shares Issued		20,000,000
Debt Conversion, Converted Instrument, Shares Issued			34,522	286,315
Debt Conversion, Original Debt, Amount (in Dollars)			$ 100,000	$ 12,703
Investment Agreement, Number of Shares	63,873,275
Investment Agreement, Value (in Dollars)	$ 5,000,000
Sale of Stock, Price Per Share (in Dollars per share)	$ 0.07828
Stock Issued During Period, Shares, New Issues	3,193,664
Proceeds from Issuance or Sale of Equity (in Dollars)	$ 250,000
Series A Convertible Preferred Stock [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Conversion of Stock, Shares Converted		20,000,000
Common Stock Issued in Settlement of Notes Payable and Accrued Interest [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued					164,270,878
Debt Conversion, Original Debt, Amount (in Dollars)					$ 242,427
Convertible Debt [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars)					242,427
Convertible Debt [Member] | Embedded Derivative Financial Instruments [Member] | Fair Value, Inputs, Level 3 [Member]
NOTE 9 - STOCKHOLDERS' EQUITY (Details) [Line Items]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers out of Level 3 (in Dollars)					$ (2,002,857)

NOTE 10 - STOCK OPTIONS AND W43

NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - USD ($)	Aug. 07, 2017	Apr. 21, 2017	Feb. 06, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 16, 2016	Nov. 02, 2015	Aug. 04, 2014	Apr. 01, 2013
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value				$ 318,150		$ 318,150
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value				$ 20,880		$ 20,880
Share Price (in Dollars per share)				$ 0.0214		$ 0.0214
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)						48,075,000
Allocated Share-based Compensation Expense				$ 396,238	$ 188,009	$ 562,928	$ 329,814
Bioheart 2013 Omnibus Equity Compensation Plan [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)								25,000,000	500,000,000	100,000	50,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in Shares)	30,000,000	25,000,000
Employee Stock Option [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options				$ 1,082,572		$ 1,082,572
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition						1 year 335 days
Employee Stock Option [Member] | Key Employees [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	23,750,000		16,200,000
Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)			$ 0.0043
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	vesting over 4 years, at grant date		vesting over 4 years, at grant date
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period	$ 860,211		$ 53,271
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%		0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	259.16%		235.22%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.81%		1.86%
Employee Stock Option [Member] | Key Employees [Member] | Minimum [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)	$ 0.03626
Employee Stock Option [Member] | Key Employees [Member] | Maximum [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)	$ 0.0368
Employee Stock Option [Member] | Director [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	8,125,000
Share-based Compensation Arranagement by Share-based Payment Award, Options, Exercise Price (in Dollars per share)	$ 0.03626
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period	$ 293,545
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	259.16%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.81%

NOTE 10 - STOCK OPTIONS AND W44

NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Option Activity - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Schedule of Option Activity [Abstract]
Options Outstanding		23,555,777
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)		$ 0.03
Options Outstanding, Weighted-Average Remaining Contractual Term	9 years 146 days	9 years 255 days
Options exercisable	20,305,459
Options exercisable, Weighted-Average Exercise Price (in Dollars per share)	$ 0.04
Options exercisable, Weighted-Average Remaining Contractual Term	9 years 109 days
Available for grant	16,408,070
Options Granted	48,075,000
Options Granted, Weighted-Average Exercise Price (in Dollars per share)	$ 0.025
Options Granted, Weighted-Average Remaining Contractual Term	10 years
Options Exercised	0
Options Forfeited/Expired	(7)
Options Forfeited/Expired, Weighted-Average Exercise Price (in Dollars per share)	$ 0.15
Options Outstanding	71,630,770
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 0.03

NOTE 10 - STOCK OPTIONS AND W45

NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Options Outstanding and Exercisable by Exercise Price Range	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Weighted-Average Remaining Contractual Term	9 years 135 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.03
Options Outstanding (in Shares) | shares	71,630,770
Options Exercisable (in Shares) | shares	20,305,459
Options Exercisable, Weighted-Average Exercise Price	$ 0.04
Options, $0.0043 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 0.0043
Options Outstanding, Weighted-Average Remaining Contractual Term	9 years 131 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.0043
Options Outstanding (in Shares) | shares	16,200,000
Options Exercisable (in Shares) | shares	0
Options Exercisable, Weighted-Average Exercise Price	$ 0
Options, $0.0196 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 0.0196
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years 357 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.0196
Options Outstanding (in Shares) | shares	22,850,000
Options Exercisable (in Shares) | shares	11,600,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.0196
Options, $0.03626 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 0.03626
Options Outstanding, Weighted-Average Remaining Contractual Term	9 years 313 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.03626
Options Outstanding (in Shares) | shares	31,865,000
Options Exercisable (in Shares) | shares	8,125,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.03626
Options, $0.03680 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 0.03680
Options Outstanding, Weighted-Average Remaining Contractual Term	9 years 313 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.03680
Options Outstanding (in Shares) | shares	10,000
Options Exercisable (in Shares) | shares	0
Options Exercisable, Weighted-Average Exercise Price	$ 0.03680
Options, $0.15402 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 0.15402
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years
Options Outstanding, Weighted-Average Exercise Price	$ 0.15402
Options Outstanding (in Shares) | shares	705,405
Options Exercisable (in Shares) | shares	580,169
Options Exercisable, Weighted-Average Exercise Price	$ 0.15402
Options, $19.32 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 19.32
Options Outstanding, Weighted-Average Remaining Contractual Term	7 years 36 days
Options Outstanding, Weighted-Average Exercise Price	$ 19.32
Options Outstanding (in Shares) | shares	150
Options Exercisable (in Shares) | shares	75
Options Exercisable, Weighted-Average Exercise Price	$ 19.32
Options, $70.00 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 70
Options Outstanding, Weighted-Average Remaining Contractual Term	3 years 335 days
Options Outstanding, Weighted-Average Exercise Price	$ 70
Options Outstanding (in Shares) | shares	100
Options Exercisable (in Shares) | shares	100
Options Exercisable, Weighted-Average Exercise Price	$ 70
Options, $210.00 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 210
Options Outstanding, Weighted-Average Remaining Contractual Term	3 years 317 days
Options Outstanding, Weighted-Average Exercise Price	$ 210
Options Outstanding (in Shares) | shares	40
Options Exercisable (in Shares) | shares	40
Options Exercisable, Weighted-Average Exercise Price	$ 210
Options, $680.00 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 680
Options Outstanding, Weighted-Average Remaining Contractual Term	2 years 131 days
Options Outstanding, Weighted-Average Exercise Price	$ 680
Options Outstanding (in Shares) | shares	40
Options Exercisable (in Shares) | shares	40
Options Exercisable, Weighted-Average Exercise Price	$ 680
Options, $5,250.00 Exercise Price [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 5,250
Options Outstanding, Weighted-Average Remaining Contractual Term	200 days
Options Outstanding, Weighted-Average Exercise Price	$ 5,250
Options Outstanding (in Shares) | shares	35
Options Exercisable (in Shares) | shares	35
Options Exercisable, Weighted-Average Exercise Price	$ 5,250

NOTE 10 - STOCK OPTIONS AND W46

NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Activity - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Schedule of Warrants Activity [Abstract]
Warrants Outstanding		139,145
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share)		$ 173.03
Warrants Outstanding, Weighted-Average Remaining Contractual Term	4 years 292 days	5 years 6 months
Warrants Exercisable	134,451
Warrants Exercisable, Weighted-Average Exercise Price (in Dollars per share)	$ 49.30
Warrants Exercisable, Weighted-Average Remaining Contractual Term	4 years 292 days
Warrants Issued	0
Warrants Exercised	0
Warrants Expired	(3,149)
Warrants Expired, Weighted-Average Exercise Price (in Dollars per share)	$ 1,767.71
Warrants Outstanding	135,996
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 136.10

NOTE 10 - STOCK OPTIONS AND W47

NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	$ 136.10		$ 173.03
Warrants Outstanding (in Shares)	135,996		139,145
Warrants Outstanding, Weighted-Average Remaining Contractual Term	4 years 292 days	5 years 6 months
Warrants Outstanding, Weighted-Average Exercise Price	$ 136.10
Warrants Exercisable (in Shares)	134,451
Warrants Exercisable, Weighted-Average Exercise Price	$ 49.30
Class of Warrants or Rights, Exercise Price Range, $0.01-$20.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding (in Shares)	94,108
Warrants Outstanding, Weighted-Average Remaining Contractual Term	5 years 73 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 15.54
Warrants Exercisable (in Shares)	94,108
Warrants Exercisable, Weighted-Average Exercise Price	$ 15.54
Class of Warrants or Rights, Exercise Price Range, $0.01-$20.00 [Member] | Minimum [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	0.01
Class of Warrants or Rights, Exercise Price Range, $0.01-$20.00 [Member] | Maximum [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	$ 20
Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding (in Shares)	29,743
Warrants Outstanding, Weighted-Average Remaining Contractual Term	4 years 109 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 24.52
Warrants Exercisable (in Shares)	29,743
Warrants Exercisable, Weighted-Average Exercise Price	$ 24.52
Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member] | Minimum [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	20.01
Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member] | Maximum [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	$ 30
Class of Warrants or Rights, Exercise Price Range, $40.01-$50.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding (in Shares)	6,253
Warrants Outstanding, Weighted-Average Remaining Contractual Term	2 years 36 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 48.36
Warrants Exercisable (in Shares)	6,253
Warrants Exercisable, Weighted-Average Exercise Price	$ 48.36
Class of Warrants or Rights, Exercise Price Range, $40.01-$50.00 [Member] | Minimum [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	40.01
Class of Warrants or Rights, Exercise Price Range, $40.01-$50.00 [Member] | Maximum [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	$ 50
Class of Warrants or Rights, Exercise Price Range, $50.01-$60.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding (in Shares)	543
Warrants Outstanding, Weighted-Average Remaining Contractual Term	3 years 292 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 60
Warrants Exercisable (in Shares)	543
Warrants Exercisable, Weighted-Average Exercise Price	$ 60
Class of Warrants or Rights, Exercise Price Range, $50.01-$60.00 [Member] | Minimum [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	50.01
Class of Warrants or Rights, Exercise Price Range, $50.01-$60.00 [Member] | Maximum [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	60
Class of Warrants or Rights, Exercise Price Range, Greater than $60.00 [Member]
NOTE 10 - STOCK OPTIONS AND WARRANTS (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrant, Exercise Price	$ 60
Warrants Outstanding (in Shares)	5,349
Warrants Outstanding, Weighted-Average Remaining Contractual Term	3 years 328 days
Warrants Outstanding, Weighted-Average Exercise Price	$ 2,988.07
Warrants Exercisable (in Shares)	3,804
Warrants Exercisable, Weighted-Average Exercise Price	$ 1,078.38

NOTE 11 - COMMITMENTS AND CON48

NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) - shares	Mar. 06, 2017	Mar. 01, 2017	Aug. 30, 2016
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Conversion of Stock, Shares Issued (in Shares)	20,000,000
Northstar Claims [Member]
NOTE 11 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Loss Contingency, Damages Sought			Northstar Biotech Group, LLC filed suit against the Company seeking a declaratory judgment as to whether its 20,000,000 Series A Preferred Shares were the subject of the Company’s reverse stock split effective November 4, 2015
Conversion of Stock, Shares Issued (in Shares)		20,000,000
Stock Issued During Period, Shares, Other (in Shares)		11,000,000
Percentage of Revenues to be Received as Royalty		10.00%
Number of Directors		2
Equity Method Investment, Ownership Percentage		5.00%

NOTE 12 - FAIR VALUE MEASUREM49

NOTE 12 - FAIR VALUE MEASUREMENT (Details)	2 Months Ended
	Mar. 08, 2017
Fair Value Disclosures [Abstract]
Percentage of Stock Price Increase	942.00%

NOTE 12 - FAIR VALUE MEASUREM50

NOTE 12 - FAIR VALUE MEASUREMENT (Details) - Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation - Warrant [Member] - Embedded Derivative Financial Instruments [Member] - Fair Value, Inputs, Level 3 [Member]	9 Months Ended
	Sep. 30, 2017USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 297,156
Net gain for the period included in earnings relating to the liabilities held at December 31, 2016	(1,891,205)
Transfers out of Level 3	(2,188,361)
Mark-to-market	1,891,205
Balance	$ 0

NOTE 13 - SUBSEQUENT EVENTS (De

NOTE 13 - SUBSEQUENT EVENTS (Details) - USD ($)	1 Months Ended	9 Months Ended
	Oct. 31, 2017	Sep. 30, 2017	Sep. 30, 2016
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Paid-in-Kind Interest (in Dollars)		$ 0	$ 193,946
Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services	1,423,647
Stock Issued During Period, Shares, Other	559,187
Paid-in-Kind Interest (in Dollars)	$ 12,704